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研究成果の概要（英文）： Because the outermost coatings of cancer cells are composed of 
cell-specific glycan layers (glycocalyx), lectins, proteins with glycan-binding potential, were 
evaluated for possible use as drug carriers in PDAC treatment. A human PDAC cell line was subjected 
to lectin microarray analysis to identify specific lectin-glycan pairs. The selected lectin was 
fused with a bacterial exotoxin for the construction of a lectin-drug conjugate (LDC), and its 
safety and anti-tumour effects were evaluated. A specific affinity between rBC2LC-N lecin and 
pancreatic cancer was identified. The IC50 of LDC 1.04 fmol/l was 1/1000 lower than that reported 
for immunotoxins. The intraperitoneal administration of LDC reduced the tumour weight, and reduced 
the number of nodules from 48 to 3 (P<0.001) and improved survival from 62 to 105 days. Herein, we 
show the concept of utilizing lectins as drug carriers to target glycans on the cancer cell surface,




様 式 Ｃ－１９、Ｆ－１９－１、Ｚ－１９、ＣＫ－１９（共通） 
１．研究開始当初の背景 
 膵癌を初めとする難治性固形癌の癌幹細






































































































の殺細胞作用を MTT 法および[3H]-leucine 
uptake assay（protein synthesis inhibition 
assay）により評価する。具体的には各種細
胞 1×104 cells を 24 穴プレートに播種し、






































































いた当結合タンパクは、 rBC2LC-N (a 


























た(生食群 MST:62日、腹腔投与群: 105 日 (P 
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